SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
|
x |
QUARTERLY REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE |
|
|
|
|
For the Quarterly Period ended March 31, 2006 |
|
|
|
|
|
o |
TRANSITION REPORT PURSUANT TO SECTION 13 OR
15(d) OF THE |
|
|
|
|
For the transition period from to . |
|
|
|
|
|
Commission file number: 0-24496 |
|
|
|
|
GEN/RX, INC.
(Exact name of registrant as specified in its charter)
|
New York |
11-2728666 |
600 Woodmere Boulevard
Woodmere, New York 11598
(Address of principal
executive offices, including zip code)
(516) 569-3800
(Registrant’s telephone
number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, $0.004 par value per share
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer o |
Accelerated filer o |
Non-accelerated filer x |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes x No o
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
|
Class |
|
Outstanding at May 13, 2006 |
|
Common Stock, $0.004 par value per share |
|
20,878,711 shares |
GEN/RX, INC.
FORM 10-Q
CONTENTS
|
|
|
|
|
|
Page |
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated Statement of Changes in Net Assets (liquidation basis) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
GEN/RX, INC.
Consolidated
Statement of Net Assets
(liquidation basis)
(in thousands, except shares and per share amounts)
|
|
|
March 31, |
|
December 31, |
|
||
|
|
|
2006 |
|
2005 |
|
||
|
ASSETS |
|
(unaudited) |
|
|
|
||
|
Cash |
|
$ |
30 |
|
$ |
31 |
|
|
|
|
|
|
|
|
||
|
LIABILITIES |
|
|
|
|
|
||
|
Accrued expenses and taxes |
|
30 |
|
31 |
|
||
|
|
|
|
|
|
|
||
|
Commitments and contingencies |
|
|
|
|
|
||
|
|
|
|
|
|
|
||
|
Net assets in liquidation |
|
$ |
0 |
|
$ |
0 |
|
|
|
|
|
|
|
|
||
|
Net assets in liquidation per common share (based on 20,878,711 |
|
$ |
0 |
|
$ |
0 |
|
See Notes to Financial Statements
1
GEN/RX, INC.
Consolidated
Statement of Changes in Net Assets
(liquidation basis)
(in thousands, except shares and per share amounts)
(unaudited)
|
|
|
January 1, |
|
January 1, |
|
||
|
Net assets — beginning of period |
|
$ |
0 |
|
$ |
0 |
|
|
|
|
|
|
|
|
||
|
Net assets in liquidation — end of period |
|
$ |
0 |
|
$ |
0 |
|
See Notes to Financial Statements
2
GEN/RX, INC.
Note 1. Financial Statements
In the opinion of management, the accompanying unaudited, consolidated, condensed financial statements contain all adjustments necessary to present fairly the financial position of the Company and its results of operations and cash flows for the interim periods presented. Such financial statements have been condensed in accordance with the applicable regulations of the Securities and Exchange Commission (“SEC”) and therefore, do not include all disclosures required by generally accepted accounting principles. These financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2005 included in the Company’s Annual Report on Form 10-K.
The results of operations for the three months ended March 31, 2006 are not necessarily indicative of the results to be expected for the entire fiscal year.
Note 2. Basis of presentation
As of July 1, 1996, the Company has adopted the liquidation basis of accounting. Accordingly, the net assets of the Company are stated at liquidation value, whereby assets are stated at their estimated net realizable values and liabilities, which include estimated liquidation expenses to be incurred through the date of final dissolution of the Company, are stated at their anticipated settlement amounts.
While the Company was engaged in operations, it was dependent on Apotex for financing. At September 1996, after the sale of AUSA to Apotex, the Company was indebted to Apotex in the amount of approximately $4,400,000. Since 1996, the Company has not made any payments to Apotex on this debt. Apotex has not charged interest on the indebtedness and has not instituted any legal proceedings for collection. It is not expected that Apotex will advance any additional funding to the Company and the Company presently has no available financing alternatives.
3
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Overview
GEN/Rx, Inc. (“GEN/Rx” or the “Company”) effectively ceased operations on or about June 30, 1996.
The Company was originally incorporated as American Veterinary Products, Inc. under the laws of the State of Colorado in 1976. In January 1988, American Veterinary Products, Inc. was acquired by Transmed Express, Inc. (“Transmed”), a publicly held company incorporated under the laws of the State of New York, in a stock-for-stock transaction. In March 1993, American Veterinary Products, Inc. changed its name to GEN/Rx, Inc.
GEN/Rx was a holding company which, through its subsidiaries, was in the business of developing, manufacturing and distributing generic injectable drugs. GEN/Rx had three wholly-owned subsidiaries: AUSA, Inc. (“AUSA”), which was sold in June 1996 to the Company’s principal stockholder and principal creditor, Apotex Corp. (formerly known as Apotex USA, Inc.; “Apotex”); American Veterinary Products, Inc. (“AVP”), which discontinued operations in December 1995; and Collins Laboratories, Inc. (“Collins”), which has been inactive since its inception.
With respect to the Company’s financial information set forth in this Quarterly Report on form 10-Q for the three months ended March 31, 2006, the financial statements are presented on a liquidation basis. The Company has not conducted any business operations since the sale of its wholly-owned subsidiary, AUSA, on June 30, 1996. All activities of the Company after such date related principally to the liquidation of the AVP assets by the receiver and the sale of AVP’s Fort Collins manufacturing plant. All of the operations of AVP and AUSA are treated as discontinued operations. No comparison is made in this report for the three months ended March 31, 2006 and March 31, 2005 because there were no operations in 2006 and 2005.
While the Company was engaged in operations, it was dependent on Apotex for financing. At September 1996, after the sale of AUSA to Apotex, the Company was indebted to Apotex in the amount of approximately $4,400,000. Since 1996, the Company has not made any payments to Apotex on this debt. Apotex has not charged interest on the indebtedness and has not instituted any legal proceedings for collection. It is not expected that Apotex will advance any additional funding to the Company and the Company presently has no available financing alternatives.
Liquidity and Capital Resources
The Company has virtually no assets and no capital resources and lacks the liquidity to carry on any business activities. Apotex is currently considering various business alternatives relating to the Company including, but not limited to, commencing new business operations, dissolving the Company or seeking an interested purchaser for its stock holdings in the Company. There can be no assurance that Apotex will pursue any of these or other alternatives relating to the Company, or if it does, that any such efforts will be successful.
4
Off-Balance Sheet Arrangements
As
of March 31, 2006, we did not have any off-balance sheet arrangements as
defined in Item 303(a)(4)(ii) of Regulation
S-K promulgated under the Securities Act of 1934, as amended.
Contractual Obligations and Commitments
As of March 31, 2006, we did not have any contractual obligations or commitments other than our outstanding debt described under “Overview” above.
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk
Market risk is the sensitivity of income to changes in interest rates, foreign exchanges, commodity prices, equity prices and other market-driven rates or prices. We are not presently engaged in any substantive commercial business. Accordingly, we are not and, until such time as we consummate a business combination, we will not be, exposed to risks associated with foreign exchange rates, commodity prices, equity prices or other market-driven rates or prices.
ITEM 4. Controls and Procedures
As of the end of the period covered by this Quarterly Report on Form 10-Q, the Company’s sole officer acting as principal executive officer and principal financial officer and director has evaluated the effectiveness of the disclosure controls and procedures of the Company. Disclosure Controls, as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended, are procedures that are designed with the objective of ensuring that information required to be disclosed in the Company’s reports filed under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure Controls are also designed with the objective of ensuring that such information is accumulated and communicated to management including the principal executive and principal financial officer as appropriate to allow timely decisions regarding required disclosure.
The Company’s management does not expect that the Company’s disclosure controls and procedures would prevent all errors and all frauds. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objective of the control system are met. Further the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all issues and instances of error and fraud, if any within a company have been identified.
As the Company currently has no operations and no revenues and only one officer, the Company has limited disclosure controls and procedures in place.
An evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures was carried out within the 90 days prior to the filing date of this report. This evaluation was carried out under the supervision and with the participation of our Acting President and Chief Executive Officer and Chief Financial
5
Officer (the “Certifying Officer”). Based upon that evaluation, the Certifying Officer concluded that the Company’s disclosure controls and procedures are adequate. There have been no significant changes in the Company’s internal controls or in other factors that could significantly affect internal controls subsequent to the date of the evaluation. If and when the Company re-commences business operations, it may seek to develop new disclosure controls and procedures.
6
The Company is not currently a party to any legal proceedings. However, the Company is indebted to Apotex in the amount of approximately $4,400,000 and has previously had a receiver appointed for its subsidiary, AVP. See “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of Part I above and “Item 3. Defaults Upon Senior Securities” below.
As a result of the failure to timely file reports under the Exchange Act relating to the Company, the Securities and Exchange Commission may, in its discretion, institute one or more actions against the Company and/or its officers and directors (and former officers and directors) seeking monetary or other penalties that may be imposed under the Exchange Act. Any such penalties could have materially adversely effect the Company.
Item 3. Defaults Upon Senior Securities
The Company has been in default on its indebtedness in favor of Apotex since 1996. The entire amount of indebtedness is due and payable. At March 31, 2006, the Company was indebted to Apotex in the amount of approximately $4,400,000.
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits
31 Rule 13a-14(a)/15d-14(a) Certification
32 Section 1350 Certification
(b) Reports on Form 8-K.
None.
7
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
GEN/Rx, Inc. |
|||
|
|
|
|
|
(Registrant) |
||
|
|
|
|
|
|
||
|
Date: May 12, 2006 |
|
|
By: |
|
/s/ Jack Margareten |
|
|
|
|
|
|
Jack Margareten |
||
|
|
|
|
|
Acting President and Chief Executive Officer, |
||
|
|
|
|
|
|
||
8
|
31 |
|
Rule 13a-14(a)/15d-14(a) Certification |
|
|
|
|
|
32 |
|
Section 1350 Certification |
9